A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions

Trial Profile

A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs INXN 2001 (Primary) ; Palifosfamide (Primary) ; Veledimex (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Sep 2015 According to Ziopharm media release, results presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
    • 05 Feb 2015 AS per NCT no of tt. arms changed from 3 to 2 and veledimex is added in tt. arms given in combination with Ad-RTS-hIL-12.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top